In NB, mutations and amplifications in the ALK (Anaplastic Lymphoma Kinase) gene correlate with an adverse prognosis, even in patients classified as being at low or intermediate risk, owing to increased ALK mRNA and protein expression [15,16,17,18,19]. This evidence concerns the gene ALK and neuroblastoma.